Shirley Ryan AbilityLab

Chicago, Illinois

OncologyantibodyPhase II

What changed

Phase II trial registered: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

6w agoTrial registeredJun 5, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
May 28, 2026
Cerebral Palsy · RECRUITING · sponsor: Shirley Ryan AbilityLab · Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy
ClinicalTrials.gov · NCT07434492 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jun 19, 2017
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma · RECRUITING · sponsor: Children's Oncology Group · Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
ClinicalTrials.gov · NCT02981628 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
6w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy
6w agoTrial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE2 registered

PHASE2 registered